SK-PHARMACY AND KHIDI HAVE STARTED COOPERATION ON THE CREATION OF MEDICAL AND PHARMACEUTICAL CLUSTERS

The Single Distributor held a meeting with representatives of the Korean Health Industry Development Institute (KHIDI), where issues of cooperation in the framework of the creation and development of medical and pharmaceutical clusters between Kazakhstan and South Korea were discussed

The meeting was attended by the Director of the KHIDI Global Health Department – Bae Ja Sop, the Director of the KHIDI Representative Office – Choi Jun Hee, the researcher of the Overseas Projects Department – Pak Hyunju, the researcher of the Overseas Projects Department – Lee Seul Ki.

A team of scientists and managers at KHIDI worked on creating a cluster infrastructure model for Kazakhstan. It should be noted that today the bilateral cooperation between the Single Distributor and KHIDI as part of the development of the cluster initiative is actively developing. Specialists of the two countries are actively exchanging experience and working on cooperation. In turn, in his presentation speech, Bae Ja Sop spoke in detail about the results of the study of the biocluster implementation model in Kazakhstan.

As international practice shows, the involvement of domestic research institutes, scientific laboratories of large medical universities like R&D centers, as well as their deployment in free economic and industrial zones, will be a great incentive for the development of medical and pharmaceutical clusters.

This important strategic direction will influence the solution of several important socially significant tasks. This is a matter of new jobs, raising the level of the scientific base, the transition to GMP standards, the creation of innovative drugs, the popularization of the domestic pharmaceutical industry and, of course, the economic development of the region in which the cluster is being built.

Combining the efforts of Kazakh companies around the creation of clusters in different regions of the country and investing in their development both from the state and private capital will ensure the growth in the production of import-substituting products and attract foreign companies to the construction of pharmaceutical plants in Kazakhstan.

In this regard, during the meeting, the parties discussed the preparation of the conclusion of a Memorandum of Understanding on cooperation on bioclusters.

At the end of the meetings, the parties mutually expressed their opinion on the importance of developing Kazakh-Korean cooperation, including in the pharmaceutical and medical industries.

Reference:

Korea Health Industry Development Institute (KHIDI) – is a government agency under the Ministry of Health and Welfare of the Republic of Korea. KHIDI Institute was founded in 1999 to provide professional and systematic support for the development of the Korean medical industry to increase its competitiveness in the global market. KHIDI is a professional institute dedicated to the global advancement of the Korean healthcare industry.

A medical-pharmaceutical cluster is a group of geographically localized interconnected innovative companies - drug developers, manufacturing companies, suppliers of equipment, components, specialized services, infrastructure facilities: research institutes, universities, technology parks, business incubators and other organizations that complement each other and enhancing the competitive advantages of individual companies and the cluster.